

BC Cancer Protocol Summary for First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin and Pembrolizumab

Protocol Code

[LUAVPCPMB](#)

Tumour Group

Lung

Contact Physician

Dr. Sophie Sun

ELIGIBILITY:

Patients must have:

- Previously untreated advanced non-small cell lung cancer, **and**
- Disease of squamous cell histology

Note:

- Patients on active treatment responding to platinum doublet chemotherapy (< 4 cycles) may be eligible to switch to [LUAVPCPMB](#). *CAP approval must be obtained.*
- Patients on active treatment with single-agent pembrolizumab are not eligible to switch to [LUAVPCPMB](#)
- **Patients who received** first-line pembrolizumab are not eligible for nivolumab or atezolizumab as any subsequent line of therapy

Patients should have:

- ECOG 0-2,
- Adequate hepatic and renal function,
- Asymptomatic/stable brain metastases (if applicable), **and**
- Access to a treatment centre with expertise to manage immune-mediated adverse reactions of pembrolizumab

EXCLUSIONS:

Patients must not have:

- Relapsed on or within *6 months* of completing adjuvant durvalumab, **or**
- Relapsed within *12 months* of completing adjuvant platinum chemotherapy

CAUTIONS:

- Active, known or suspected autoimmune disease
- Patients with long term immunosuppressive therapy or systemic corticosteroids (requiring more than 10 mg predniSONE/day or equivalent)

TESTS:

- **Baseline:** CBC & differential, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH, morning serum cortisol, chest x-ray, camera nuclear renogram for GFR (if available)
 - C-reactive protein and albumin (optional, and results do not have to be available to proceed with first treatment)
- **Before each treatment:** CBC & differential, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH
- **If clinically indicated:** chest x-ray, morning serum cortisol, lipase, glucose, serum or urine HCG (required for women of child bearing potential if pregnancy suspected), free T3 and free T4, serum ACTH levels, testosterone, estradiol, FSH, LH, ECG
- Weekly telephone nursing assessment for signs and symptoms of side effects while on treatment (Optional).

PREMEDICATIONS:

PACLitaxel must not be started unless the following drugs have been given:

- **If no prior infusion reactions to pembrolizumab:** administer premedications as sequenced below
45 minutes prior to PACLitaxel:
 - dexamethasone 20 mg IV in 50 mL NS over 15 minutes30 minutes prior to PACLitaxel:
 - diphenhydrAMINE 50 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible)
- **If prior infusion reactions to pembrolizumab:** administer PACLitaxel premedications prior to pembrolizumab
45 minutes prior to pembrolizumab:
 - dexamethasone 20 mg IV in 50 mL NS over 15 minutes30 minutes prior to pembrolizumab:
 - diphenhydrAMINE 50 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible)acetaminophen 325 to 975 mg PO prior to pembrolizumab
- Antiemetic protocol for moderate emetogenic chemotherapy (see SCNAUSEA)

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
pembrolizumab	2 mg/kg (maximum 200 mg)	IV in 50 mL NS over 30 minutes Using a 0.2 micron in-line filter*
PACLitaxel	200 mg/m ²	IV in 250 to 500 mL NS over 3 hours use non-DEHP bag and non-DEHP tubing with 0.2 micron in-line filter*
CARBOplatin	AUC 5 or 6 Dose = AUC x (GFR** + 25)	IV in 100 to 250 mL NS over 30 minutes

* use separate infusion line and filter for each drug

** GFR may be determined by nuclear renogram or estimated by the Cockcroft formula, at the discretion of the attending physician:

$$\text{GFR} = \frac{N \times (140 - \text{age in years}) \times \text{wt (kg)}}{\text{Serum creatinine (micromol/L)}} \quad N = 1.04 \text{ (women) or } 1.23 \text{ (men)}$$

The estimated GFR should be capped at 125 mL/min when it is used to calculate the initial CARBOplatin dose. When a nuclear renogram is available, this clearance would take precedence.

- **Repeat every 3 weeks x 4 cycles**
- **Maintenance treatment to begin 21 to 42 days after last cycle; see LUAVPMBM or LUAVPMBM6**

DOSE MODIFICATIONS:**1. HEMATOLOGY**

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Dose
greater than or equal to 1.0	and	greater than or equal to 100	100%
less than 1.0	or	less than 100	Delay until recovery

- Other toxicities:** No specific dose modifications for pembrolizumab. Toxicity managed by treatment delay and other measures (see [SCIMMUNE](#) protocol for management of immune-mediated adverse reactions to checkpoint inhibitors immunotherapy, http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Supportive%20Care/SCIMMUNE_Protocol.pdf).

3. **Arthralgia and/or myalgia:** If arthralgia and/or myalgia of grade 2 (moderate) or higher is not relieved by adequate doses of NSAIDs or acetaminophen with codeine (e.g., **TYLENOL #3®**), a limited number of studies report a possible therapeutic benefit using:
 - predniSONE 10 mg PO bid x 5 days starting 24 hours post-PACLitaxel
 - gabapentin 300 mg PO on day before chemotherapy, 300 mg bid on treatment day, then 300 mg tid x 7 to 10 days
 - If arthralgia and/or myalgia persists, reduce subsequent PACLitaxel doses to 175 mg/m².
4. **Neuropathy:** Dose modification or discontinuation may be required (see BC Cancer Drug Manual).
5. **Renal dysfunction:** If significant increase (greater than 20%) in creatinine, repeat nuclear renogram (if available) and recalculate CARBOplatin dose using new GFR.
6. **Hepatic dysfunction:** Dose reduction may be required for PACLitaxel (see BC Cancer Drug Manual)

PRECAUTIONS:

1. **Serious immune-mediated reactions:** can be severe to fatal and usually occur during the treatment course with pembrolizumab, but may develop months after discontinuation of therapy. They may include enterocolitis, intestinal perforation or hemorrhage, hepatitis, dermatitis, neuropathy, endocrinopathy, pneumonitis, as well as toxicities in other organ systems. Early diagnosis and appropriate management are essential to minimize life-threatening complications (see [SCIMMUNE](#) protocol for management of immune-mediated adverse reactions to checkpoint inhibitors immunotherapy, http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Supportive%20Care/SCIMMUNE_Protocol.pdf).
2. **Infusion-related reactions:** isolated cases of severe infusion reactions have been reported with pembrolizumab. Discontinue pembrolizumab with severe reactions (Grade 3 or 4). Patients with mild or moderate infusion reactions may receive pembrolizumab with close monitoring and use of premedication.

3. Hypersensitivity: Reactions are common with PACLitaxel. See BC Cancer Hypersensitivity Guidelines.

<i>mild</i> symptoms (e.g. mild flushing, rash, pruritus)	<ul style="list-style-type: none"> ▪ complete PACLitaxel infusion. Supervise at bedside ▪ no treatment required
<i>moderate</i> symptoms (e.g. moderate rash, flushing, mild dyspnea, chest discomfort, mild hypotension)	<ul style="list-style-type: none"> ▪ stop PACLitaxel infusion ▪ give IV diphenhydrAMINE 25-50 mg and IV hydrocortisone IV 100 mg ▪ after recovery of symptoms resume PACLitaxel infusion at 20 mL/hr for 5 minutes, 30 mL/hr for 5 minutes, 40 mL/hr for 5 minutes, then 60 mL/hr for 5 minutes. If no reaction, increase to full rate. ▪ if reaction recurs, discontinue PACLitaxel therapy
<i>severe</i> symptoms (i.e. <i>one</i> or more of respiratory distress requiring treatment, generalized urticaria, angioedema, hypotension requiring therapy)	<ul style="list-style-type: none"> ▪ stop PACLitaxel infusion ▪ give IV antihistamine and steroid as above. Add epinephrine or bronchodilators if indicated ▪ discontinue PACLitaxel therapy

4. Extravasation: PACLitaxel causes pain and may, rarely, cause tissue necrosis if extravasated. Refer to BC Cancer Extravasation Guidelines.

5. Neutropenia: Fever or other evidence of infection must be assessed promptly and treated aggressively.

Contact Dr. Sophie Sun or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES:

1. Merck Canada: KEYTRUDA (pembrolizumab) product monograph. Kirkland, Quebec: 20 July 2017.
2. Postow M, Wolchok J. Toxicities Associated With Checkpoint Inhibitor Immunotherapy. UpToDate revised 2015. Accessed: www.uptodate.com, May 2016.
3. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
4. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer. N Engl J Med. 2018;379(21):2040-51.
5. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.